Duvelisib was the next PI3K inhibitor authorised through the FDA, also depending on a period III randomized demo.130 The efficacy and basic safety profile on the drug seem equivalent with These of idelalisib, Otherwise a bit advantageous. About substitute BTK inhibitors, there are many products in growth, but only acalabrutinib is authorized via th